舒格利单抗一线治疗非小细胞肺癌的快速卫生技术评估

打开文本图片集

【中图分类号】R979.1 【文献标识码】A

Sugemalimab as first-line treatment for non-small cell lung cancer： a rapid health technologyassessment

HOU Yibing1， KANG Shuo²， GONG Yuan³，WANG Xiaohui²， NIE Ying^，LIU Huanlong²

1. Deparment of Pharmacy， The Second Hospital of Hebei Medical University， Shijiazhuang 050000，China

2.Medical Insurance Office， The Second Hospital of Hebei Medical University， Shijiazhuang 050000，China

3.CollegeofPharmacy，HebeiMedical University，Shijiazhuang O5oo17，China

Corresponding author：LIU Huanlong，Email： Ihlong1026@163.com

【Abstract】 Objective To evaluate the efficacy， safety and economy of sugemalimab in the first-line treatment of non-small cell lung cancer （NSCLC） by rapid health technology assessment.MethodsPubMed， Cochrane Library，Embase，CNKI，WanFang Data，VIPand official websites of health technology assessment （HTA） institutions were systematically searched to collect HTA reports， systematic reviews/Meta-analysis and pharmacoeconomic studies of sugemalimab in first-line treatment of NSCLC from inception to October 31，2024.Two reviewers independently screened the literature，extracted information and performed quality asessment of the included studies，and then performed descriptive analysis on theresults.Results A total of15 articles were selected，including 4 systematic reviews/Meta-analysis and 11 pharmacoeconomic studies.In terms of efectiveness，compared with chemotherapy alone，sugemalimab combined with chemotherapy significantly improved progresion-free survival （PFS），overallsurvival （OS），and objective response rate （ORR） in patients with NSCLC.In terms of safety，compared with chemotherapy alone， sugemalimab combined chemotherapy had higher incidence of overall adverse events，but it had a beter safety profile compared to other immune combination therapies.In terms of economy， most studies suggested that compared with chemotherapy alone， sugemalimab combined with chemotherapy was not cost-effctive， which may be related to the high price of sugemalimab.However，afew studies indicated that sugemalimab combined with chemotherapy could be cost-effctive in specific scenarios. Conclusion Sugemalimab has good efficacy in the first-line treatment of NSCLC，but its safety and economy need to be further studied.

【Keywords】 Sugemalimab; Non-small cell lung cancer; Effectiveness; Safety; Economics; Rapid health technology assessment

癌症作为严重危害人类健康的重大慢性疾病，已成为全球主要死亡原因之一。（剩余17126字）